BTK and susceptibility to pneumonia measurement: A higher incidence of pneumonia was observed in patients who previously received anti-CD20 therapy (30.0% vs. 16.3%, P=0.048) and BTK inhibitor therapy (51.3% vs. 22.5%, P=0.001).